Global Information
회사소개 | 문의

클로스트리듐 디피실 감염증 : 파이프라인 리뷰

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 10월 상품 코드 255954
페이지 정보 영문 210 Pages
가격
US $ 2,000 ₩ 2,287,800 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,575,600 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,863,400 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


클로스트리듐 디피실 감염증 : 파이프라인 리뷰 Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H2 2018
발행일 : 2018년 10월 페이지 정보 : 영문 210 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

클로스트리듐 디피실 감염증은 클로스트리듐 디피실로 불리는 세균에 의해서 발생하는 감염증으로, 설사에서 결장의 치명적인 감염증까지 폭넓은 증상을 일으킵니다. 증상은 복통이나 압통을 수반하는 수양성 설사, 식욕 감퇴, 열, 피나 고름이 섞인 변, 체중 감소 등입니다. 위험인자는 연령, 소화관 수술, 면역력 저하, 신장병, 위산을 줄이는 프로톤펌프저해제 사용 및 화학요법약 사용 등입니다. 이러한 증상은 항생물질 같은 약물의 사용으로 관리하거나 생활습관의 수정에 의해서 예방할 수 있습니다.

세계 각국의 클로스트리듐 디피실 감염증(Clostridium difficile Infections) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 파이프라인 제품의 최신 동향, 임상시험 각 단계의 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

서론

  • 조사 범위

클로스트리듐 디피실 감염증(클로스트리듐 디피실 관련 질환) 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 파이프라인 제품
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

클로스트리듐 디피실 감염증(클로스트리듐 디피실 관련 질환) : 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

클로스트리듐 디피실 감염증(클로스트리듐 디피실 관련 질환) 치료제 개발에 참여하고 있는 기업

  • Absynth Biologics Ltd
  • Actelion Ltd
  • AIMM Therapeutics BV
  • Akthelia Pharmaceuticals Ltd
  • AmpliPhi Biosciences Corp
  • Appili Therapeutics
  • Assembly Biosciences Inc
  • AvidBiotics Corp
  • C3J Therapeutics Inc
  • CaroGen Corp
  • Crestone Inc
  • Da Volterra SAS
  • Daiichi Sankyo Company Ltd
  • Evec Inc
  • GangaGen Inc
  • ImmunoBiology Ltd
  • Immuron Ltd
  • Inovio Pharmaceuticals Inc
  • Integrated BioTherapeutics Inc
  • Merck & Co Inc
  • MGB Biopharma Ltd
  • Microbiotix Inc
  • Micropharm Ltd
  • Miyarisan Pharmaceutical Company Ltd
  • Nabriva Therapeutics AG
  • Nanotherapeutics Inc
  • Novabiotics Ltd
  • NovoBiotic Pharmaceuticals LLC
  • Oragenics Inc
  • Otsuka Holdings Co Ltd
  • Pfizer Inc
  • Prokarium Ltd
  • Rebiotix Inc
  • Sanofi Pasteur SA
  • Second Genome Inc
  • Seres Therapeutics Inc
  • Serometrix LLC
  • Sorrento Therapeutics Inc
  • Summit Therapeutics Plc
  • Synthetic Biologics Inc
  • Valevia UK Ltd
  • Valneva SE
  • XBiotech Inc

약제 개요

휴지중인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

KSM 17.06.20

List of Tables

  • Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Absynth Biologics Ltd, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Akthelia Pharmaceuticals Ltd, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Appili Therapeutics Inc, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Assembly Biosciences Inc, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AzurRx BioPharma Inc, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by CaroGen Corp, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Chain Biotechnology Ltd, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Crestone Inc, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by DEINOVE SA, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Evec Inc, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Evotec AG, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Ferring International Center SA, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Immune Biosolutions Inc, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by ImmuneBiotech AB, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by ImmunoBiology Ltd, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Immuron Ltd, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals Inc, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Inspyr Therapeutics Inc, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Integrated BioTherapeutics Inc, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Merck & Co Inc, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MGB Biopharma Ltd, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Micropharm Ltd, H2 2018
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Novabiotics Ltd, H2 2018

List of Figures

  • Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridium difficile Infections - Pipeline Review, H2 2018, provides an overview of the Clostridium difficile Infections (Infectious Disease) pipeline landscape.

Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Clostridium difficile Infections - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Clostridium difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 8, 11, 37, 13 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 6 molecules, respectively.

Clostridium difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Clostridium difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Clostridium difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Clostridium difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Clostridium difficile Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Clostridium difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Overview
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Development
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Drug Profiles
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products
  • Clostridium difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones
  • Appendix
Back to Top
전화 문의
이용안내
 
BCC Research